News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
684,064 Results
Type
Article (38991)
Company Profile (277)
Press Release (644796)
Section
Business (203838)
Career Advice (1987)
Deals (35358)
Drug Delivery (84)
Drug Development (80774)
Employer Resources (168)
FDA (16086)
Job Trends (14800)
News (344486)
Policy (32431)
Tag
Academia (2530)
Alliances (49041)
Alzheimer's disease (1218)
Approvals (16006)
Artificial intelligence (122)
Bankruptcy (352)
Best Places to Work (11489)
Biotechnology (196)
Breast cancer (111)
Cancer (968)
Cardiovascular disease (82)
Career advice (1657)
Cell therapy (209)
Clinical research (64000)
Collaboration (339)
Compensation (173)
COVID-19 (2523)
C-suite (85)
Data (940)
Diabetes (140)
Diagnostics (6113)
Earnings (84489)
Employer resources (146)
Events (109114)
Executive appointments (256)
FDA (16551)
Funding (301)
Gene therapy (153)
GLP-1 (566)
Government (4320)
Healthcare (18659)
Infectious disease (2602)
Inflammatory bowel disease (102)
Interviews (308)
IPO (16275)
Job creations (3623)
Job search strategy (1415)
Layoffs (409)
Legal (7849)
Lung cancer (158)
Manufacturing (159)
Medical device (13152)
Medtech (13157)
Mergers & acquisitions (19120)
Metabolic disorders (375)
Neuroscience (1462)
NextGen Class of 2024 (6497)
Non-profit (4463)
Northern California (1304)
Obesity (223)
Opinion (177)
Patents (96)
People (56158)
Phase I (19867)
Phase II (28179)
Phase III (21033)
Pipeline (320)
Postmarket research (2553)
Preclinical (8452)
Radiopharmaceuticals (234)
Rare diseases (189)
Real estate (5888)
Regulatory (21460)
Research institute (2307)
Resumes & cover letters (349)
Southern California (1163)
Startups (3560)
United States (12285)
Vaccines (541)
Weight loss (163)
Date
Today (232)
Last 7 days (1068)
Last 30 days (3276)
Last 365 days (35457)
2024 (31168)
2023 (40075)
2022 (51173)
2021 (55712)
2020 (54087)
2019 (46542)
2018 (35019)
2017 (32110)
2016 (31480)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (188)
Asia (37044)
Australia (6040)
California (2936)
Canada (1207)
China (224)
Colorado (127)
Connecticut (131)
Europe (79308)
Florida (415)
Georgia (104)
Illinois (320)
Indiana (187)
Kansas (96)
Maryland (543)
Massachusetts (2374)
Michigan (146)
Minnesota (257)
New Jersey (868)
New York (876)
North Carolina (674)
Northern California (1304)
Ohio (129)
Pennsylvania (780)
South America (1091)
Southern California (1163)
Texas (404)
Utah (84)
Washington State (335)
684,064 Results for "ardelyx inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Ardelyx, Inc. Reports Employment Inducement Grants - May 30, 2024
Ardelyx, Inc. today announced that on May 23, 2024, the compensation committee of the company’s board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company’s common stock.
May 30, 2024
·
1 min read
Genetown
Ardelyx, Inc. Reports Employment Inducement Grants - May 14, 2024
Ardelyx, Inc. announced that on May 6, 2024, the compensation committee of the company’s board of directors granted 26 new non-executive employees options to purchase an aggregate of 511,500 shares of the company’s common stock, and granted 32 new non-executive employees an aggregate of 425,050 Restricted Stock Units.
May 14, 2024
·
1 min read
Press Releases
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference
November 5, 2024
·
1 min read
Genetown
Ardelyx Presents Additional Data Detailing Educational Needs Related to IBS-C Management Across Healthcare Disciplines
Ardelyx, Inc. today announced that data detailing educational needs related to irritable bowel syndrome with constipation (IBS-C) across healthcare disciplines was presented via a poster at the 2024 American Association of Nurse Practitioners (AANP) Annual Conference.
June 28, 2024
·
4 min read
Genetown
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
Ardelyx, Inc. (Nasdaq: ARDX) today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time in New York City.
May 22, 2024
·
1 min read
Genetown
Ardelyx, Inc. Reports Employment Inducement Grants - March 12, 2024
Ardelyx, Inc. announced that on March 9, 2024, the compensation committee of the company’s board of directors granted nine new non-executive employees options to purchase an aggregate of 207,038 shares of the company’s common stock, and granted twelve new non-executive employees an aggregate of 157,450 Restricted Stock Units.
March 12, 2024
·
2 min read
Press Releases
Ardelyx Reports Third Quarter 2024 Financial Results and Provides Business Update
October 31, 2024
·
14 min read
Genetown
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
Ardelyx, Inc. today announced that data supporting additional positive clinical observations of XPHOZAH ® (tenapanor) was presented in a series of poster presentations at the National Kidney Foundation (NKF) 2024 Spring Clinical Meetings, now underway in Long Beach.
May 16, 2024
·
6 min read
Press Releases
Ardelyx to Report Third Quarter 2024 Financial Results on October 31, 2024
October 17, 2024
·
1 min read
Business
Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today reported financial results for the first quarter ended March 31, 2024 and provided a business update.
May 2, 2024
·
11 min read
1 of 68,407
Next
